Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study-Reference-Cited by-同舟云学术

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Published:2021-11 Issue:11 Volume:3 Page:e789-e797
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Moor Matthias B,Suter-Riniker Franziska,Horn Michael P,Aeberli Daniel,Amsler Jennifer,Möller Burkhard,Njue Linet M,Medri Cesare,Angelillo-Scherrer Anne,Borradori Luca,Radonjic-Hoesli Susanne,Seyed Jafari S Morteza,Chan Andrew,Hoepner Robert,Bacher Vera Ulrike,Mani Laila-Yasmin,Iype Joseena Mariam,Hirzel Cédric,Maurer Britta,Sidler Daniel

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference33 articles.

1. Age-specific mortality and immunity patterns of SARS-CoV-2;O'Driscoll;Nature,2021

2. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak;Portolés;Nephrol Dial Transplant,2020

3. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China;Liang;Lancet Oncol,2020

4. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting;Dagan;N Engl J Med,2021

5. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 in the immunocompromised host;COVID-19: An Update;2024-09-01

2. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy;Journal of Allergy and Clinical Immunology;2024-09

3. A Case Report and Literature Review of a Triple-Vaccinated, Rituximab-Treated Systemic Lupus Erythematosus patient with COVID-19 pneumonia;ARP Rheumatology;2024-06-30

4. Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases;JCI Insight;2024-06-04

5. Rituximab‐to‐vaccine interval on SARS‐CoV‐2 immunogenicity in children: The potential role of prior natural infection;Pediatric Allergy and Immunology;2024-05